Opening book details…
Can I read Modulatory Act of Diverse Transcriptional Factors in Liver Carcinoma on EtoBox?
Modulatory Act of Diverse Transcriptional Factors in Liver Carcinoma by Rashmi Nagesh; Rajeshwari H. Patil; M. Naveen Kumar; K.M. Kiran Kumar; Shivaleela Biradar; Babu R. Lamani is a book available to read on EtoBox.
What is Modulatory Act of Diverse Transcriptional Factors in Liver Carcinoma about?
Hepatic cancer is the sixth most common cancer and the third leading cause of cancer-associated mortalities globally. Among different forms of liver cancer, hepatocellular carcinoma (HCC) alone reports for more than 75% of liver cancer occurrences. HCC develops in hepatocytes, the prime cells of liver tissue. They are often to the result of excessive alcoholic consumption, hepatitis B or hepatitis C viral infection, or exposure to dietary toxicants, which result in cirrhosis and contribute to 70%À80% of cases of liver cancer. Owing to poor prognosis and lack of treatment availability, the morbidity rate due to HCCs has increased to a great extent. Early detection can aid in better therapeutic approaches, such as radiofrequency ablation, partial hepatectomy, or liver transplantation. Designing of new therapeutic strategies depends on diverse criteria such as understanding the pathophysiological characteristics of tumor, the severity of hepatic failure, age, medical complications, and available medical facilities. Therefore it is crucial to comprehend the altered biological events that cause HCC. Numerous studies have reported the aberrant activation of many signaling cascades in ins
- Author
- Rashmi Nagesh; Rajeshwari H. Patil; M. Naveen Kumar; K.M. Kiran Kumar; Shivaleela Biradar; Babu R. Lamani
- Published
- 2022
- Language
- EN
More by Rashmi Nagesh; Rajeshwari H. Patil; M. Naveen Kumar; K.M. Kiran Kumar; Shivaleela Biradar; Babu R. Lamani
Similar books
- Nanotherapeutics for the Treatment of Hepatocellular Carcinoma — Mukherjee Biswajit (2022)
- Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma — Aaron Coleman; Elainea N. Smith; Samuel J. Galgano; Kristin K. Porter (2023)
- Hepatic TM6SF2 Activates Antitumour Immunity to Suppress Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma and Boosts Immunotherapy — Yating Zhang (2025)
- Molecular Biology and Immunology in Hepatology : Advances in the Treatment of Intractable Liver Diseases — T. Tsuji, Toshiaki Higashi, M. Zeniya, K. -H. Meyer zum Buschenfelde (2002)
- Hepatic Functional Deterioration in Chronic Liver Disease — Ryosuke Tateishi (2024)
- Liver Carcinogenesis : the Molecular Pathways — George G Skouteris; North Atlantic Treaty Organization Scientific Affairs Division; NATO Advanced Study Institute on Molecular Aspects of Liver Carcinogenesis (2013)